本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002250 证券简称：联化科技 公告编号：2025-024 联化科技股份有限公司 关于召开 2024 年度股东大会的通知 网络投票时间为：2025年6月9日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年6 月9日9:15至9:25，9:30至11:30和13:00至15:00；通过深圳证券交易所互联网投票 系统投票的具体时间为：2025年6月9日9:15至15:00。 一、召开会议基本情况 1、股东大会届次：2024年度股东大会 2、股东大会的召集人：联化科技股份有限公司（以下简称"公司"、"联化 科技"）第八届董事会第二十三次会议决议提请召开股东大会。 3、会议召开的合法、合规性：本次股东大会会议的召集、召开符合有关法 律、行政法规、部门规章、规范性文件和《公司章程》的规定。 4、会议召开的日期、时间： 现场会议时间为：2025年6月9日（星期一）13时30分 （1）截至2025年6月3日下午收市后在中国证券登记结算公司深圳分公司登 5、会议的召开方式：本次股东大会以现场表决 ...

此议案需提交2024年度股东大会审议。 《2024年度监事会工作报告》全文详见巨潮资讯网（www.cninfo.com.cn）。 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 联化科技股份有限公司（以下简称"公司"）第八届监事会第十次会议通知 于2025年4月11日以电子邮件方式发出。会议于2025年4月23日在联化科技会议室 以现场表决的方式召开。会议应出席监事3人，实际出席监事3人。会议由监事会 主席冯玉海先生召集和主持，符合《公司法》、《证券法》等法律法规、部门规章、 规范性文件及《公司章程》的有关规定。会议形成如下决议： 一、会议以3票同意，0票反对，0票弃权的表决结果，审议并通过《2024年 度监事会工作报告》。 证券代码：002250 证券简称：联化科技 公告编号：2025-016 联化科技股份有限公司 第八届监事会第十次会议决议公告 二、会议以3票同意、0票反对、0票弃权的表决结果，审议并通过《2024年 度财务决算报告》。 此议案需提交2024年度股东大会审议。 具体内容详见披露于巨潮资讯网（www.cninfo.com.cn）上的公司《20 ...

证券代码：002250 证券简称：联化科技 公告编号：2025-015 联化科技股份有限公司 第八届董事会第二十三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 联化科技股份有限公司（以下简称"公司"）第八届董事会第二十三次会议 通知于2025年4月11日以电子邮件方式发出。会议于2025年4月23日在联化科技会 议室以现场表决的方式召开。会议应出席董事7人，实际出席董事7人。公司监事、 高级管理人员列席了本次会议，会议由董事长王萍女士召集和主持，符合《公司 法》、《证券法》等法律法规、部门规章、规范性文件及《公司章程》的有关规定。 会议形成如下决议： 一、会议以7票同意，0票反对，0票弃权的表决结果，审议并通过《2024年 度总裁工作报告》。 二、会议以7票同意，0票反对，0票弃权的表决结果，审议并通过《2024年 度董事会工作报告》。 此议案需提交2024年度股东大会审议。 《 2024 年 度 董 事 会 工 作 报 告 》 的 具 体 内 容 详 见 披 露 于 巨 潮 资 讯 网 （www.cninfo.com.cn）上的公司《202 ...

证券代码：002250 证券简称：联化科技 公告编号：2025-018 联化科技股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、审议程序 联化科技股份有限公司（以下简称"公司"）于2025年4月23日召开第八届董 事会第二十三次会议、第八届监事会第十次会议，审议通过了《2024年度利润分 配预案》，本议案尚需提交公司股东大会审议，现将有关情况公告如下： 二、利润分配预案的基本情况 根据立信会计师事务所（特殊普通合伙）出具的信会师报字[2025]第11221号 审计报告，2024年度母公司实现的净利润156,917,873.10元，提取盈余公积 15,691,787.31元，支付2023年度股东股利18,226,662.34元，加上年初未分配利润 为2,189,322,816.79元，本次可供股东分配的利润2,312,322,240.24元。 本着公司发展与股东利益兼顾原则，公司2024年度利润分配预案为：以未来 实施分配方案时股权登记日的公司总股本剔除回购专用证券账户已回购股份 11,459,900股后 ...

联化科技股份有限公司 联化科技股份有限公司全体股东： 我们审计了联化科技股份有限公司(以下简称"联化科技")2024 年度的财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债 表、2024 年度合并及母公司利润表、合并及母公司现金流量表、合并 及母公司所有者权益变动表和相关财务报表附注，并于 2025 年 4 月 23 日出具了报告号为信会师报字[2025]第 ZA11221 号的无保留意见 审计报告。 联化科技管理层根据中国证券监督管理委员会《上市公司监管指 引第 8 号——上市公司资金往来、对外担保的监管要求》（证监会公 告〔2022〕26 号）和《深圳证券交易所上市公司自律监管指南第 1 号 ——业务办理（2023 年修订）》的相关规定编制了后附的 2024 年度 非经营性资金占用及其他关联资金往来情况汇总表（以下简称"汇总 表"）。 编制汇总表并确保其真实、准确、合法和完整是联化科技管理层 的责任。我们将汇总表所载信息与我们审计联化科技 2024 年度财务 报表时所审核的会计资料及已审计财务报表中披露的相关内容进行 了核对，没有发现在重大方面存在不一致的情况。 专项报告第 1 页 ...

联化科技股份有限公司 内部控制审计报告 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了联化科技股份有限公司（以下简称联化科技）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、 企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定，建立健全和有效实施内部控制，并评 价其有效性是联化科技董事会的责任。 二、 注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的 有效性发表审计意见，并对注意到的非财务报告内部控制的重大缺陷 进行披露。 三、 内部控制的固有局限性 二〇二四年度 内部控制审计报告 信会师报字[2025]第 ZA11222 号 联化科技股份有限公司全体股东： （特殊普通合伙） 立信会计师事务所 中国注册会计师：戴金燕 中国注册会计师：陈剑 中国•上海 二〇二五年四月二十三日 内控审计报告 第 2 页 内部控制具有固有局限性，存在不能防止和发现错报的可能性。 此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策 和程序遵循的程度降低，根据内部控制审计结果推测未来内部控制的 ...

联化科技股份有限公司 审计报告及财务报表 二○二四年度 联化科技股份有限公司 审计报告及财务报表 （2024 年 01 月 01 日至 2024 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-4 | | 二、 | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | | 财务报表附注 | 1-128 | 审 计 报 告 信会师报字[2025]第 ZA11221 号 联化科技股份有限公司全体股东： 一、 审计意见 我们审计了联化科技股份有限公司（以下简称联化科技）财务报 表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度 的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所 有者权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的 规定编制，公允反映了 ...

联化科技（002250）公告，2024年营业收入为56.77亿元，同比下降11.88%。归属于上市公司股东的净 利润1.03亿元，同比增长122.17%。基本每股收益0.1118元/股。公司拟向全体股东每10股派发现金红利 0.2元(含税)，送红股0股(含税)，不以公积金转增股本。 ...

Dividend Distribution - The company plans to distribute a cash dividend of 0.2 RMB per 10 shares to all shareholders, based on the total share capital excluding repurchased shares[4]. - The board of directors has approved the profit distribution plan, which will be executed on the share registration date[4]. - The company reported a cash dividend total of ¥97,812,841.16, which represents 100% of the total profit distribution amount[197]. - The distributable profit available for shareholders was ¥2,312,322,240.24, with a net profit of ¥156,917,873.10 for the fiscal year 2024[197]. - The company aims to maintain a minimum cash dividend ratio of 80% during profit distribution, reflecting its mature development stage[197]. - The cash dividend policy is compliant and transparent, with clear decision-making processes in place[196]. - The company has ensured that minority shareholders have opportunities to express their opinions and that their rights are protected[196]. Financial Performance - The company's operating revenue for 2024 was approximately ¥5.68 billion, a decrease of 11.88% compared to ¥6.44 billion in 2023[22]. - The net profit attributable to shareholders for 2024 was ¥103.14 million, a significant turnaround from a loss of ¥465.24 million in 2023, representing a 122.17% increase[22]. - The net profit after deducting non-recurring gains and losses for 2024 was ¥121.38 million, up 134.31% from a loss of ¥353.82 million in 2023[22]. - The net cash flow from operating activities increased by 14.83% to ¥1.24 billion in 2024, compared to ¥1.08 billion in 2023[22]. - The company's total assets at the end of 2024 were approximately ¥13.80 billion, a slight decrease of 0.80% from ¥13.91 billion at the end of 2023[22]. - The company's weighted average return on equity improved to 1.51% in 2024, compared to -6.68% in 2023, marking an increase of 8.19 percentage points[22]. - The company's financial expenses increased by 249.17% to ¥73,601,547.13, primarily due to reduced foreign exchange gains[120]. - The research and development expenses decreased by 22.53% to ¥291,064,608.45[120]. - R&D investment decreased by 22.53% from 375,716,722.56 CNY in 2023 to 291,064,608.45 CNY in 2024, representing 5.13% of revenue[122]. - The number of R&D personnel decreased by 11.30% from 761 in 2023 to 675 in 2024, with a notable decline in those under 30 years old by 16.34%[122]. - The company's cash flow from financing activities decreased by 49.82%, from 3,928,464,301.60 CNY in 2023 to 1,971,308,652.69 CNY in 2024[125]. - The total amount of accounts receivable increased by 0.87%, from 1,113,422,910.64 CNY in 2023 to 1,225,529,334.94 CNY in 2024[124]. Market Trends and Projections - The global crop protection industry is projected to reach a market size of approximately $75 billion in 2024, with a compound annual growth rate of 2.6% over the next five years[30]. - The global pharmaceutical market is projected to reach $1,718.8 billion by 2025 and $2,114.8 billion by 2030, with a compound annual growth rate (CAGR) of 4.2%[38]. - The global innovative drug market is expected to grow to $1,222.7 billion in 2025 and $1,545.5 billion in 2030, indicating a significant market share increase[38]. - China's pharmaceutical market is forecasted to reach ¥2,064.5 billion by 2025 and ¥2,739.0 billion by 2030, with a CAGR of 5.8%[39]. - The global CDMO market is anticipated to grow to $124.3 billion by 2025 and $231.0 billion by 2030, with a CAGR of 13.2%[40]. - China's CDMO market is projected to reach ¥157.1 billion by 2025, accounting for 19.6% of the global market, and ¥355.9 billion by 2030, representing 23.9% of the global market[40]. - The personal care and cosmetics market in China is expected to grow from ¥182.5 billion in 2014 to ¥435.7 billion in 2024, with a CAGR of 9.09%[46]. Research and Development - The company has established multiple R&D platforms to meet diverse customer needs across different stages of product development, enhancing its competitive edge in the agricultural protection sector[51]. - The company is actively expanding its CDMO and CRO services in the pharmaceutical sector, focusing on collaboration with major global pharmaceutical companies[56]. - The company aims to develop a series of specialized solvents and functional additives for the new energy market, leveraging its technological advantages in fine chemicals[58]. - The company has a strong technical innovation and incubation capability, recognized by global leading companies in the plant protection and pharmaceutical sectors[70]. - The company has accumulated rich technical reserves and process development experience over years of exploration in the chemical field[71]. - The company is focusing on R&D cooperation projects in the plant protection sector, aiming to enhance core competitiveness through resource integration and product development[76]. - The company has successfully applied efficient ligand catalysis and palladium recovery technology in commercial production, reducing precious metal usage and production costs[76]. - The company has upgraded its production technology, achieving breakthroughs in continuous nitration, diazotization, and photochemical reactions, improving safety and yield[80]. - The company aims to develop green enzyme catalysis technology and has made significant progress in establishing a fermentation platform for biopesticides and biofertilizers, with potential for large-scale production by 2025[76]. Operational Strategy - The company is expanding its market presence in the petrochemical, coal chemical, and new energy sectors by enhancing technical applications and product upgrades, transitioning from a single equipment manufacturer to a multi-solution provider[82]. - The company has established a comprehensive international management system, integrating safety, quality, environmental protection, and supply chain management, which has created a high management barrier in the industry[83]. - The company is committed to continuous investment in technology innovation and global supply chain layout to maintain its leading position in the industry[52]. - The company is constructing a new facility in Malaysia to diversify its supply chain and mitigate potential risks, with plans to provide more diversified solutions based on product lifecycle[90]. - The company is focusing on technological innovation and lean management to reduce manufacturing costs and improve operational efficiency[90]. - The company will continue to focus on sustainable development and enhance its SHEQ&C management system across various sectors, including agriculture, pharmaceuticals, and fine chemicals[150]. - The company acknowledges risks from macroeconomic fluctuations and environmental regulations, implementing strategies to mitigate these risks and enhance competitiveness[159][160]. - The company faces significant raw material cost fluctuations due to ongoing global conflicts and environmental issues, impacting operational performance[162]. - To mitigate risks, the company will enhance supply chain management and diversify product types to reduce reliance on single raw materials[162]. Governance and Management - The company has established a governance structure that complies with relevant laws and regulations, ensuring strong independence and standardized operations[170]. - The board consists of seven directors, with three independent directors, meeting legal requirements and ensuring diverse expertise[171]. - The company maintains complete independence from its controlling shareholder in terms of business, personnel, assets, and finance, ensuring autonomous operations[174]. - The company has implemented a stock incentive plan for subsidiaries to align interests between shareholders and key personnel, promoting long-term stability[171]. - The company has a dedicated financial department with an independent accounting system, ensuring financial decision-making autonomy[174]. - The company has a robust information disclosure system, ensuring timely and accurate communication with investors and regulatory bodies[173]. - The company has established a transparent performance evaluation and incentive mechanism for management, enhancing accountability and alignment with corporate goals[171]. - The total number of shares held by the board and management reflects a strong commitment to the company, with significant personal investments noted[178]. - The company’s governance structure includes a mix of experienced professionals from various industries, enhancing its strategic decision-making capabilities[179][180]. Employee Engagement and Training - The total number of employees at the end of the reporting period is 5,403, with 958 in the parent company and 4,445 in major subsidiaries[190]. - The company conducted 5,222 internal offline training sessions in 2024, totaling 7,032 hours and reaching 85,279 participants[193]. - The company offers 188 online learning courses, with 1,238 participants in 2024[193]. - The company has 39 employees with doctoral degrees and 230 with master's degrees, reflecting a diverse educational background[190]. - The company emphasizes internal fairness in its compensation management, aligning salaries with job responsibilities and market conditions[191]. - The company has implemented a performance evaluation system to determine variable bonuses based on employee contributions[191]. Compliance and Risk Management - The company has established a comprehensive internal control system covering itself and 15 subsidiaries, ensuring effective governance and compliance[200]. - The internal control evaluation process included interviews, discussions, and sampling to identify and rectify deficiencies[200]. - Currency fluctuations, particularly in USD, can impact profits, and the company will continue to execute foreign exchange hedging strategies to mitigate this risk[165]. - The company has a comprehensive value management system and is focused on enhancing valuation through strategic initiatives[168]. - The company has disclosed its "Quality and Return Dual Improvement" action plan to enhance operational quality and shareholder returns[168].

4月14日，联化科技今日收盘6.24元，上涨1.96%，最新市净率0.89，总市值56.87亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)10联化科技-15.91-12.220.8956.87亿行业平均 47.6847.152.6059.65亿行业中值40.1337.501.7550.06亿1苏利股份-352.39133.881.1426.88亿2回盛生 物-109.41298.323.7950.06亿3先达股份-92.77-92.771.1823.74亿4申联生物-52.12-52.121.6323.74亿5长青股 份-32.0343.000.7131.44亿6国发股份-29.67-31.533.0625.95亿7雅本化学-27.51-72.112.6359.34亿8丰山集 团-24.38-52.871.4120.71亿9ST红太阳-21.43-21.259.0382.68亿11中农联合-13.25-11.221.5221.59亿 截至2024年三季报，共有129家机构持仓联化科技，其中基金129家，合计持股数3263.83万股，持股市 值1.80亿元。 来源：金融界 联化科技股份有限公司主 ...